Company intelligence / Profile preview

CorNeat Vision

Ownership: Private
Development stage: Commercial

Overview

CorNeat Vision has achieved FDA clearance for its EverPatch+ synthetic scleral reinforcement matrix. Its flagship artificial cornea device (CorNeat KPro) has completed first-in-human trials with successful restoration of vision in patients with corneal blindness. The company’s glaucoma drainage device and periodontal matrix are at various stages of development and clinical validation[3][4][5].

Therapeutic areas: OtherOphthalmology
Modalities: DeviceBiologic (biomimetic implants)Synthetic implant
Industry: Implantable Medical Devices

Drug pipeline

3 assets

EverPatch

Commercial

Indications: Ocular surface surgery, Glaucoma surgery

2 more assets in the full pipeline.

Request access →

Partnerships

Not specified in public sources as of June 2025.

Beyond the preview

Go deeper on CorNeat Vision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorNeat Vision.

Explore the full profile